Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado. Show more

Location: 6200 Lookout Road, Boulder, CO, 80301, United States | Website: https://www.enliventherapeutics.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

1.241B

52 Wk Range

$13.30 - $30.03

Previous Close

$20.95

Open

$20.96

Volume

310,255

Day Range

$19.95 - $21.02

Enterprise Value

751.1M

Cash

490.5M

Avg Qtr Burn

-17.65M

Insider Ownership

8.89%

Institutional Own.

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ELVN-001 Details Chronic Myeloid Leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELVN-002 w/ trastuzumab +/- chemotherapeutic agents Details Cancer, Metastatic breast cancer, Metastatic colorectal cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ELVN-002 monotherapy Details Cancer, Solid tumor/s, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.